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muscle during exercise is unclear. We developed and validated a mathematical model of AMPK 23 signaling dynamics, and then applied global parameter sensitivity analyses with data-informed 24 constraints to predict that AMPK activity dynamics are determined principally by ADP and not 25 AMP. We then used the model to predict the effects of two additional direct-binding activators of 26 AMPK, ZMP and Compound 991, further validating the model and demonstrating its applicability 27 to understanding AMPK pharmacology. The relative effects of direct-binding activators can be 28 understood in terms of four properties, namely their concentrations, binding affinities for AMPK, 29 abilities to enhance AMPK phosphorylation, and the magnitudes of their allosteric activation of 30 AMPK. Despite AMP's favorable values in three of these four properties, ADP is the dominant 31 controller of AMPK activity dynamics in skeletal muscle during exercise by virtue of its higher 32 concentration. 33 34 Introduction 50
Physical exercise training induces profound fitness-promoting adaptations in skeletal muscle cells 51 AMPK is phosphorylated at the Thr-172 residue within the activation loop of the α-subunit [13] . 80 Several kinases and phosphatases control the phosphorylation state of this site in vivo. The 81 principal kinases include liver kinase B1 (LKB1) and calmodulin-dependent protein kinase kinase 82 β (CAMKKβ) [14] , and the main phosphatases include phosphoprotein phosphatases 1 and 2A 83 (PP1, PP2A), and metal-dependent protein phosphatase 2C (PP2C) [15] [16] [17] . ADP and AMP inhibit 84 AMPK dephosphorylation and promote AMPK phosphorylation by LKB1 [14, 18] . ATP inhibits 85 AMPK phosphorylation by competing with ADP and AMP for binding to AMPK and by 86 stabilizing it in a conformation that favors its dephosphorylation [17] . AMP allosterically activates 87 AMPK catalytic activity by 1.5-to 13-fold, depending on the estimate, by binding to cystathionine-88 β-synthase (CBS) domains within the  subunit [14, 19, 20] . Overall, how these factors interact to 89 regulate overall AMPK activity is poorly understood. 90
Two principal hypotheses have been proposed to explain AXP-mediated control of AMPK activity 91 in vivo. One hypothesis posits that AMP (or its ratio with ATP) is the primary controller of AMPK 92 [21, 22] . Three lines of argument support this hypothesis. First, AMP is proposed to act as a more 93 sensitive controller of AMPK activity than ADP for a given amount of ATP breakdown because 94 the adenylate kinase reaction involves ATP and AMP interconverting into two ADP, such that the 95 AMP:ATP ratio would vary as the square of the ADP:ATP ratio [23] . Second, AMP enhances the 96 activity of LKB1 towards specific isoforms of AMPK by up to four fold [14, 20] , whereas ADP 97 enhances LKB1 activity only by 1.5-fold [14] . Third, only AMP allosterically activates AMPK 98 [14, 19, 20] . Overall, AMP is more potent on a per-molar basis than ADP in activating AMPK 99 [20, 22] , which ultimately reflects a higher per-molecule activation potency, i.e., the degree of 100 activation per AMPK molecule upon the binding of activator. 101
An alternative hypothesis is that ADP is the primary controller of AMPK activity. The main 102 arguments for this hypothesis is that the concentration of free ADP is orders of magnitude higher 103 than that of free AMP (50-200 M versus 0.5-5 M) [17, 18, [24] [25] [26] and that ADP and AMP both 104 bind to the AMPK -subunit nucleotide-binding site 3 with roughly similar affinities [26] . Because 105 of the comparable affinities of binding and the higher ADP concentration, ADP-mediated 106 protection of phospho-AMPK from dephosphorylation is posited to be critical to the in vivo control 107 of AMPK activity [26] . Furthermore, data from human exercise studies show that the concentration 108 of ADP exceeds its dissociation constant (KD) of binding to site 3 on the  domain, whereas the 109 concentration of AMP does not, thus implying that ADP outcompetes AMP for binding to that site 110 [18] . In accordance, ADP levels and AMPK activities increase in parallel as a function of exercise 111 intensity [18] . 112
Despite the rich in vitro and in vivo data available regarding AMPK activity control, these 113 hypotheses await definitive support or refutation because of the complex and quantitative nature 114 of AMPK control. Complexities include the dynamic variation of AXP concentration with exercise 115 intensity, the effects of the comparable yet quantitatively different binding affinities of the AXPs 116 towards the γ isoforms [26, 27] , and the different per-molecule activation potencies of the AXPs 117 towards AMPK. These factors are challenging to parse experimentally. Accordingly, a more 118 complete understanding of AMPK activation in vivo requires the study of these mechanisms using 119 methods that account for these complexities. 
Model description 141
A schematic diagram of the model topology is presented in Figure 1 . The model is briefly described 142 here, with comprehensive details and justification provided in the Supplementary Methods. The 143 system is defined as a muscle fiber with average contractile, metabolic, and fatigability properties 144 contracting within a primary agonist muscle during cycling exercise. In the spectrum from slow to 145 fast-twitch fibers, the fiber would most closely resemble a type-IIa fiber [33] . The model is 146 expressed as a system of ordinary differential equations that describe the rates of change of the 147 represented molecular species. The model consists of three modules: 1) bioenergetic, 2) AMPK 148 regulatory, and 3) pharmacological activator (PA). The bioenergetic module simulates AXP 149 dynamics in response to exercise and is based on published models [34, 35] . The input to the model 150 were the parameters describing the rates of ATP hydrolysis under different conditions (krest, kstim, 151 kpost; Table S4 ). These parameters were set to values that led the predicted phosphocreatine 152 concentrations to match measured values. The outputs of the model were the predicted phospho-153 AMPK (p-AMPK) levels and the activities of the various AMPK species. The activity of a 154 molecular species was calculated as the product of its concentration and corresponding kcat 155 parameter. Model species and initial conditions, reaction rate equations, ordinary differential 156 equations, and parameter values are presented in Tables S1, S2 When simulating the effects of ZMP, the module features r22 and r23 as well as r24 and r25, which 172 represents the interconversion of AICAR, the precursor molecule, to ZMP (r24) and ZMP 173 degradation (r25). Activator-specific parameter values are used for r22 and r23. 174
175

Model calibration 176
The model parameter values (Tables S4, S5 , S6, and S7) were calibrated by using estimates from 177 published literature, biochemical calculations, and manual adjustment to fit the model to data from 178 exercising humans. The calibration is described in detail in the Supplementary Methods. 179
Model validation 180
To externally validate the model, the predictions of the calibrated model were were calculated using the 'cumtrapz' function, and the model was numerically integrated using the 241 'ode23s' algorithm using default tolerances. We also solved the model using alternative solvers and 242 confirmed that our choice of solver did not affect the model results. 243
244
Results 245
Bioenergetic module simulation of AXP dynamics 246
The AMPK model predicts AMPK dynamics resulting from AXP dynamics during exercise. The 247 experimental data for AMPK signaling against which our model was compared came from the 248 vastus lateralis of humans during cycling exercise. Hence, we first verified whether the 249 bioenergetic module, which was based on a model of metabolism in contracting forearm skeletal 250 muscle [34], could adequately simulate AXP dynamics in this different mode of exercise [5] . The 251 concentrations of PCr, inorganic phosphate (Pi), and the AXPs were predicted to achieve steady 252 states at ~10 min following the onset of exercise (Fig. 2) . The PCr concentration decreased from 253 23 mM to 17 mM and the Pi concentrations increased from 2.6 mM to 8.7 mM ( Fig. 2A ). ATP 254 concentration was essentially preserved at its resting levels of 7.7 mM, which matched the data 255 well ( Fig. 2B ). ADP and AMP increased by 1.8-fold (49 μM to 91 μM) and 3.4-fold (0.43 μM to 256 1.5 μM), respectively, which also matched well their experimentally observed values ( Fig. 2B) . 257
These results demonstrate that the bioenergetic module satisfactorily explained AXP dynamics in 258 vastus lateralis during cycling exercise. 259 
Model calibration results and predicted AMPK dynamics during continuous submaximal exercise 271
Next, we calibrated the model to AMPK signaling data and evaluated the predicted AMPK activity 272 dynamics. Initial simulations revealed that the model with the pre-calibration parameter values 273 caused the phospho-AMPK levels to rise and fall unrealistically fast. Guided by the local parameter 274 sensitivity analysis, we found that this discrepancy could be reduced by lowering the kinase and 275 phosphatase parameters from their pre-calibration values (40-47, Table S4 ). The kinetic 276 parameters pertaining to AXP-AMPK binding were also adjusted (Table S4) . KeqADK was 277 decreased to better reflect human tissue in which the intracellular Mg 2+ differs from the reported 278 data (Table S4 ). Collectively, these changes slowed the rate of AMPK phosphorylation and 279 dephosphorylation and increased free AMP levels, such that the model predictions better matched 280 experimental measurements. 281
The calibrated model predicted the following features of the AMPK dynamics in skeletal muscle 282 during exercise. First, the concentration of phospho-AMPK increased from 34% to 45% of the 283 total amount of AMPK (Fig. 2C ). The total kinase activity of phospho-AMPK increased ~30% 284 during exercise, 94% of which was attributable to the ADP-bound form of phospho-AMPK, 2% 285 to the AMP-bound form (Fig. 2D ), and the remainder to the other phospho-AMPK species. On 286 average, the experimental data showed that AMPK activity increased ~40% after 30-minutes of 287 exercise [5] . To better match the model output to the data, we tried increasing the Vmax values for 288 AMPK phosphorylation (parameters 40-43, Table S4 ). While this strategy led to better fits of the 289 activity data, it also caused the rise in phospho-AMPK levels to be excessively rapid, such that the 290 resulting fit is a compromise. 291
Model validation and AMPK dynamics during sprint-interval exercise 292
Next, we validated the calibrated model using the data of Gibala et al. [6] , in which both PCr and 293 relative phospho-AMPK levels were measured in response to four 30-s sprint intervals interspersed 294 with 4 min of passive recovery. We set the kstim parameter (Table S5) In the α1β2γ1 KD MPSA, the model was sensitive to the dissociation rate constants for ADP-p-360 AMPK (k10r) and AMP-p-AMPK (k11r), as indicated by the K-S statistics and Spearman 361 correlations (Supplementary Spreadsheet "MPSA" worksheet). However, the shifts in the 362 quantiles for the KD and KD ratios incorporating these parameters were relatively minor and not 363 visually different compared to those that did not incorporate the k10r and k11r parameters (Fig.  364   S2A) . In contrast, sensitivities were evident for the Vmax and KM parameters for the AMPK kinase 365 and phosphatase. The K-S statistics and Spearman correlations for the Vmax and KM of the ADP-366 AMPK kinase (VmaxKinaseADP and KM16, respectively) were the highest amongst the enzyme kinetic 367 parameters (Supplementary Spreadsheet "MPSA" worksheet). These results were corroborated by 368 the boxplots, which additionally showed that the sensitivities propagated into the corresponding 369 Vmax/KM ratio for the ADP-AMPK kinase, the quantile values of which were higher in ADP-370 dominant models compared to AMP-dominant models (Fig. S2B ). The sensitivities also 371 propagated into the higher-order ratios incorporating this Vmax/KM ratio (Fig. S2B, bottom panel) . 372
The parameter to which the model was most sensitive in the α1β2γ1 KD MPSA was KeqADK, which 373 is part of the adenylate kinase reaction rate equation (reaction 5, Supplementary Table S2 ). This 374 parameter strongly associated with the concentration of AMP (Fig. S2C ), which is one of the 375 determinants in Equation S8. The K-S statistic and Spearman correlation coefficient for KeqADK 376 were 0.56 and 0.46, respectively, both of which were the highest observed in the α1β2γ1 KD MPSA 377 (Supplementary Spreadsheet "MPSA" worksheet). The boxplots revealed lower medians for 378 KeqADK, higher medians for maximum AMP concentration (~7 μM vs. 2 μM), lower medians for 379 ADP/AMP concentration ratios, and higher AMP allostery (~8 vs. 5-fold) for the AMP-dominant 380 models (Fig. S2C ). Collectively, these results show that AMP-dominant control can occur when 381 changes to parameters other than those determining AXP-(p)-AMPK binding affinities are made. 382
Similar results were observed from the α2β2γ3 KD MPSA, except that the model was not sensitive 383 to the binding rate constants because their sampling ranges were tightly constrained (Fig. S3A) . 384
The K-S statistics and Spearman correlations were highest for the Vmax and KM of the ADP-AMPK 385 kinase (VmaxKinaseADP, KM16) and KeqADK (Supplementary Spreadsheet "MPSA" worksheet). These 386 results were corroborated by the boxplots, which showed a prominent upward shift in the Vmax/KM 387 of the ADP-AMPK kinase for the ADP-dominant models (Fig. S3B, top right panel) . The K-S 388 statistics and Spearman correlation coefficients for the Vmax and KM of the AMP-AMPK kinase 389 (VmaxKinaseAMP and KM18, respectively) were slightly elevated (Supplementary Spreadsheet 390 "MPSA" worksheet), and the boxplots showed a downward shift in the Vmax/KM ratio for the ADP-391 p-AMPK phosphatase (Fig. S3B, top right panel) . Boxplots revealed lower medians for KeqADK, 392 higher medians for maximum AMP concentration (~4.5 μM vs. 2 μM), lower medians for 393 ADP/AMP concentration ratios, and similar AMP allostery (1.4-to 1.5-fold) for the AMP-394 dominant models (Fig. S3C) . Collectively, the α2β2γ3 KD MPSA revealed that AMP-dominant 395 models are possible given the uncertainties in the parameter values, especially given the more 396 pronounced differences in KD values for AMPK binding to AMP and ADP. 397
AMP-dominant models from the α2β2γ3 KD MPSA are implausible 398
The results from the α2β2γ3 KD MPSA indicated that AMP-dominant control of AMPK activity 399 is possible given plausible sampling ranges for the parameter values. However, careful inspection 400 of the Vmax/KM ratio plots revealed that these values for the ADP-AMPK kinase were shifted to 401 lower values than those for ATP-AMPK in the AMP-dominant models from both the α1β2γ1 KD 402 and α2β2γ3 KD MPSAs (top right panels for Fig. S1B, S2B, S3B ). This result contradicts data 403 indicating that ADP enhances the rate of AMPK phosphorylation by its kinases compared to ATP 404 [14, 20, 41] , such that these models are implausible. We proceeded to ask how many AMP-405 dominant models from the α2β2γ3 KD MPSA featured unrealistic parameter values or otherwise 406 dubious predictions that would invalidate these models, which could lead to a more definitive 407 conclusion regarding AXP-mediated AMPK activity control. 408 For each acceptable model in the α2β2γ3 KD MPSA, we evaluated the plausibility of the maximum 409 AMP concentration, the relative values of Vmax/KM ratios for the ADP-AMPK and ATP-AMPK 410 kinases and phosphatases, and the relative Vmax values for the same molecular species. Of the 2,685 411 acceptable models, 1,295 featured <0.8 fraction ADP control, thus indicating substantial 412 contribution of AMP to AMPK activity control. Of these 1,295 models, 365 featured plausible free 413 AMP concentrations, i.e., less than 2.92 μM, which is the highest measured value in studies of 414 AMPK signaling in humans in response to moderate-intensity exercise [5,42-45] (see Figs. S1C, 415 S2C, and S3C, middle panels). 164 simulations featured Vmax/KM values for ADP/AMP-AMPK 416 kinase that were lower than those for ATP-AMPK kinase ( Fig. 4A and 4B ) and were deemed 417 implausible. Of the 164 remaining models, 99 featured ADP/AMP-AMPK kinase Vmax values that 418 were lower than those of the ATP-AMPK kinase Vmax (Fig. 4A and 4C) . Similarly, the Vmax/KM 419 values for the ADP/AMP-p-AMPK phosphatase were higher than those of the ATP-p-AMPK 420 phosphatase in 35 of 99 remaining models ( Fig. 4A and 4D ). Of the 64 remaining models, 16 421 featured higher Vmax values for the ADP/AMP-p-AMPK phosphatase compared to the ATP-p-422 AMPK phosphatase ( Fig. 4A and 4E ). This process of elimination left 48 models of the starting 423 1,295 acceptable models from the α2β2γ3 KD MPSA. The same process was executed on the 1,390 424 simulations that had >0.8 fraction ADP control, of which 279 had appropriate kinetics in the final 425 subset (Fig. 4A) . 426
To evaluate the plausibility of the 48 remaining models, we compared the values of the Vmax/KM 427 ratios for the ADP-(p)-AMPK and AMP-(p)-AMPK kinases and phosphatases. Experimental data 428
indicates that these parameters are likely different and in manners that favor AMP control; 429 however, they are unlikely to be substantially different based on their measured dose response 430 curves [14, 20] , which we conservatively defined for the analysis as 100-fold. In 29 of the 48 431 models, we observed that at least one of the Vmax or KM parameters was 100-fold different in the 432 direction favoring the creation of AMP-p-AMPK or the removal of ADP-p-AMPK 433 (Supplementary Spreadsheet "48 models" worksheet). In the remaining 19 models, the highest 434 share of AMP-p-AMPK as a contributor to total AMPK activity was 32%, compared to 68% 435 contributed by ADP-p-AMPK. 436
Finally, we examined the model-predicted time courses of AMP-p-AMPK, ADP-p-AMPK, and 437 total phospho-AMPK from the 48 models to look for patterns that might explain the increased 438 degree of AMP control in these cases. For the AMP-dominant models, the total phospho-AMPK 439 was low by comparison to ADP-dominant models (Fig. 4, lower We first confirmed that the model was able to reproduce observed intramuscular ZMP 478 concentrations over time in response to AICAR perfusion (Fig. 5A) [46]. All parameter values 479 relating to ZMP-mediated AMPK activation were obtained from reports of independent 480 measurements and were not otherwise calibrated to the data. The model predicted that ZMP 481 elicited similar levels of phospho-AMPK but higher AMPK activities than those elicited by 482 moderate exercise ( Fig. 5B and 5C ). The model-predicted phospho-AMPK activities corresponded 483 well to experimental measurements (Fig. 5C) . 484
Similar to ZMP, we substituted parameter values from independent in vitro experiments to 485 simulate the effects of C991. In response to bolus addition of C991, the model predicted increasing 486 levels of phospho-AMPK and AMPK activity as the dose of C991 increased from 10 -4 mM to 10 -487 2 mM. Each simulation agreed well with the experimental data ( Fig. 5B and 5C) [47]. The 10 -2 488 mM dose of C991 elicited the lowest phospho-AMPK levels but the highest AMPK activity, as 489 compared to AICAR and moderate exercise ( Fig. 5B and 5C ). Together, these results suggest that 490 the model generalizes to direct-binding AMPK activators. 491
Next, we summarized how the properties of the different AMPK activators integrate to produce 492 emergent AMPK activation by simulating the dose response curves of each activator. The model 493 qualitatively reproduced the sigmoidal shape expected for these relationships (Fig. 5D ). The model 494 also predicted that C991 elicits the highest AMPK activities of the four when applied at its 495 experimentally applied concentrations, followed in order by ZMP, ADP, and AMP (Fig. 5D, filled  496 portions of the curves). While AMP has the potential to be the most potent activator of AMPK 497 based on three of four determinants (Equation S8), its low concentration in vivo causes it to rank 498 last amongst the activators. 499 activators. To simulate perfusion of AICAR, we assumed that its concentration remained 503
unchanged throughout the simulation. The concentration of ZMP was fitted to published data. B) 504
Time courses of phospho-AMPK (p-AMPK) concentrations for each simulation. C) Total AMPK 505
activities for each simulation. The "" and the "+" markers denote measured AMPK activities in 506 response to ZMP and Compound 991, respectively. D) Dose response of AMPK activities in 507 response to treatment with Compound 991, ZMP, ADP, and AMP. The model was simulated 508 independent of the bioenergetic module by removing reactions 1-5 and setting the AXP = 0 except 509 if added exogenously, in which case its total concentration was held constant by setting generation 510 and degradation reaction rates to zero. The reactions were simulated for 240 minutes and the 511 steady-state values plotted. The filled portions under each curve indicate the ranges of activator 512 concentrations that are either measured (AMP, ADP) or experimentally applied (ZMP, Compound 513 991). 514 515
Discussion 516
In this study, we developed and analyzed a mathematical model of AMPK signaling in human 517 skeletal muscle to systematically investigate AXP-mediated control of AMPK activity dynamics 518 during exercise. The model incorporates the known mechanisms of AXP-mediated AMPK 519 activation in a single unified framework, thus allowing for their study in context of one another. 520
We applied global parameter sensitivity analysis guided by a simple theoretical framework and 521 data-informed constraints to predict that AMPK activity dynamics in skeletal muscle during 522 exercise are determined principally by ADP and not AMP. Furthermore, we showed that our model 523 can predict the effects of other direct-binding AMPK activators, thus demonstrating its usefulness 524 for understanding AMPK pharmacology. 525
Our conclusion is based on the following interpretations of our results. First, we showed that the 526 calibrated model predicted that ADP-p-AMPK contributed over 90% to the total AMPK activity 527 during continuous and sprint-interval exercise. While striking, we could not straightforwardly 528 conclude ADP-dominant control because many of the model's parameter values are uncertain. To 529 analyze the model in the context of these uncertainties, we employed global parameter sensitivity 530 analyses in which the predictions from ensembles of models featuring parameter values sampled 531 from plausible ranges were analyzed. The MPSA revealed that AMP-dominant control is possible 532 for many parameter sets. However, introducing data-informed constraints on free AMP 533 concentrations, the relative enhancement of AMPK phosphorylation when bound to ADP 534 compared to ATP, and the relative protection of phospho-AMPK from dephosphorylation when 535 bound to ADP compared to AMP, led to the elimination of all models featuring AMP-dominant 536 control. Of the remaining plausible models, the highest contribution of AMP to AMPK activity 537 control was 32%, compared to 68% for ADP. Collectively, these results imply that ADP is the 538 dominant controller of AMPK activity dynamics in exercise. 539
Our study contributes significant new understanding to a longstanding debate regarding how 540 AMPK activity is controlled by the adenine nucleotides. AMP has long been considered the 541 principal controller of AMPK activity, which is reflected in the name of the enzyme [48]. However, 542 subsequent structural studies showed that ADP could also control AMPK activity, and some 543 proposed that ADP is the predominant controller of AMPK activity in vivo [24, 26] . Evidence in 544 support of AMP as the "true" physiological regulator then followed [20, 22] , and the debate 545 remains unresolved to date. The crux of the debate is whether the stronger per-molecule activation 546 potency of AMP outweighs the two-orders-of-magnitude higher concentration of ADP in cells. 547
Resolving the debate will require accurate estimates of these quantities and accounting for them 548 in a unified framework. Our study presents a new mathematical model of AMPK signaling that 549 explicitly includes these factors and accounts for the full range of corresponding estimates 550 available in the literature. Quantitative models and arguments have been proposed in prior work 551 [24, 49] but these were based on steady-state considerations, whereas our model considers 552 dynamics. Existing dynamic models of AMPK signaling [28-31] only considered AMP as the 553 activating nucleotide and were applied to cell types other than skeletal muscle. In addition, unlike 554 these previous studies, ours was the first to consider estimates from the AMPK isoforms and ones 555 from studies featuring results supporting AMP-dominant control, in particular the 13-fold 556 allosteric activation of the α1β2γ1 isoform by AMP reported by Gowans et al. [20] . In this way, 557 our model integrated all pertinent knowledge to evaluate AXP-mediated control of AMPK activity 558 in a systematic, comprehensive, and fair manner. The model can be easily updated as new estimates 559 become available. 560
Our study may find additional utility for studying AMPK activity dynamics during exercise and 561 for studying small-molecule activators of AMPK. Studying signaling dynamics in exercising 562 humans or animals is currently difficult because it relies on biochemical analyses of biopsied 563 muscle. Since only a few biopsies can be ethically sampled from any one individual, these 564 approaches cannot be used to measure the full dynamic profile of AMPK activity in response to a 565 bout of exercise. Mathematical models provide interpolated estimates between the data points, thus 566 helping to "fill in the blanks." The promise of the AMPK model for the proposed application is 567 evident from the simulations of both continuous and sprint-interval exercise (Fig. 2 & 3 ). The latter 568
shows the accumulation of AMPK activity with each interval despite lengthy (4 min) rest periods, 569 which provides clues regarding how sprint-interval exercise can be so potent for inducing fitness-570 promoting adaptations in skeletal muscle despite the minimal time spent exercising [50] . 571
Our model provides a general framework for evaluating small-molecule activators of AMPK, 572 which are being studied as therapeutics for muscle and metabolic dysfunction and as part of 573 exercise-mimetic cocktails [10, 51] . Typically, AMPK activators have been identified on the basis 574 of binding affinity and enhanced substrate phosphorylation [51, 52] . Early AMPK activators 575 featured properties based on AMP given its greater per-molecule potency of activation relative to 576 other activators such as ADP [53] [54] [55] . However, these criteria are insufficient for predicting 577 therapeutic suitability because they do not consider factors such as the molecule's ability to protect 578 AMPK from dephosphorylation, its pharmacokinetics, or the duration of its action once in the cell 579
[51]. Indeed, our results imply that designing a molecule that faithfully mimics AMP's properties 580 would not work well because its concentration would be too low. Indeed, the ZMP precursor 581 AICAR is applied in experiments at millimolar concentrations, which after uptake and processing 582 leads to intracellular ZMP concentrations that exceed those of AMP by at least two orders of 583 magnitude (Fig. 5 ). We recommend that drug developers assess candidate AMPK activators based 584 on all the factors expressed in Equation S5, rather than just a subset as is current practice. More 585 broadly, integrated approaches to drug design are being advanced in the emerging field of 586 quantitative systems pharmacology [56], and our model could find use as the pharmacodynamic 587 portion of future physiologically based pharmacokinetic-pharmacodynamic models of small 588 molecules targeting AMPK. 589
Our study features four noteworthy limitations. First, AMP is likely still crucial to the function of 590 AMPK in vivo, owing to AMP's tight and relatively permanent binding to the -subunit nucleotide-591 binding site 4 of AMPK, the function of which remains to be discovered [12] . Our conclusion 592 regarding ADP-dominant control is restricted to the dynamic variation of AMPK activity during 593 exercise. Second, the model incorporates the simplifying assumptions that the cell is a well-mixed 594 reactor and does not account for possible stochastic effects, spatial concentration gradients, or 595 restrictions on localization. Accounting for stochastic and spatial effects is unlikely to affect our 596 conclusions because the concentrations of AMPK signaling components are sufficiently high to 597 be deterministically modeled and because AMP and ADP must exist in the same cellular 598 compartments due to their participation in the same biochemical reactions, e.g., the adenylate 599 kinase reaction. Spatially restricted AMP concentration gradients of sufficient magnitude to 600 outcompete ADP as the main controller of AMPK are unlikely to exist. 601
Third, we assumed that the parameter values of the model were constant within each simulation, 602 despite the knowledge that exercise imposes generalized biophysical and biochemical effects on 603 cells, such as changes in water content [57], temperature [58], and pH [59], which could cause the 604 parameter values to be nonconstant. Such changes are unlikely to alter our findings for two reasons. 605
First, changes in intramuscular conditions are more extreme in sprint-interval exercise than in 606 continuous submaximal-intensity exercise, yet the calibrated model was able to reproduce 607 phospho-AMPK kinetics to sprint-interval exercise without changes to parameter values. Second, 608 the MPSA sampled parameter values from ranges well beyond possible variation during exercise, 609 yet the finding of ADP-dominant control was robust across these simulations. 610
Finally, our results depend on accurate measurements of AMP and ADP concentrations available 611 to participate in biochemical reactions in cells, which are subject to uncertainties. Notably, 612 disparate estimates exist for the concentrations of free and total AXP. At rest, most estimates 613 suggest that the free AMP:ATP ratio is ~100-fold less than the free ADP:ATP ratio [26,60] 614 whereas estimates of the total AMP:ATP ratio is ~10-fold less than the total ADP:ATP ratio 615 [23, 61] . Furthermore, the free concentrations of ADP and AMP are not directly measured but are 616 based on calculations that depend on the assumption that the creatine-kinase and adenylate-kinase 617 reactions operate close to equilibrium, whereas total AXP are directly measured biochemically 618 using high-performance liquid chromatography techniques. In principle, estimates from the latter 619 should be given more weight. These issues are unlikely to affect our conclusions for two reasons. 620
First, the apparent discrepancies in the measurements of free and total AXP suggest the existence 621 of pools of AXP tightly bound to cellular structures. These bound AXP would remain unavailable 622 to AMPK, in which case only the free concentrations are relevant to its control. Second, HPLC-623 based measurements of AXP during and after exercise frequently find no change in the levels of 624 AMP between rest and exercise [42,59,61-63], which if true, obviates total AMP as a possible 625 controller of AMPK dynamics during exercise. 626
In summary, we have developed and analyzed a mathematical model of AMPK signaling in 627 skeletal muscle during exercise. Our analyses demonstrate that ADP rather than AMP dominates 628 the control of AMPK activity dynamics. More generally, activators of AMPK must feature a 629 sufficient combination of per-molecule activation potency, binding affinity, and concentration to 630 be effective in vivo. Our model provides a tool for systematically investigating these factors for 631 any direct-binding AMPK modulator. 
